LIPA and atherosclerosis: Reciprocally, the ability of our analysis pipeline to identify LIPA as an ASCVD risk driver, further supported by our PheWAS-MR and atherosclerotic plaque RNA-seq analysis, reinforces the robustness of our approach in detecting cell-specific genetic drivers of ASCVD risk.